Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer

Researchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working.

21 Mar 2024

NUS study reveals key mechanisms behind drug resistance in relapsed acute myeloid leukemia

Scientists from the National University of Singapore (NUS) have discovered that the evasion of apoptosis is a key driver of drug resistance in patients with relapsed acute myeloid leukaemia (AML), a type of aggressive blood cancer.

19 Mar 2024

The efficacy of the Mediterranean diet on health outcomes in adults with cancer

A new study published in Nature explores the safety and benefits of this diet in adults with cancer, in addition to its feasibility in this population.

15 Mar 2024

Innovative therapy targets and destroys leukemia stem cells

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells.

26 Feb 2024

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

St. Jude Children's Research Hospital scientists improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.

12 Feb 2024

FDA’s plan to ban hair relaxer chemical called too little, too late

In April, a dozen years after a federal agency classified formaldehyde a human carcinogen, the Food and Drug Administration is tentatively scheduled to unveil a proposal to consider banning the chemical in hair-straightening products.

8 Feb 2024

Proteogenomics provides clues about drug response in acute myeloid leukemia

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

6 Feb 2024

Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

2 Feb 2024

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

NewsMedical speaks with Chao Ma, Ph.D. a Research Assistant Professor at New York University Tandon School of Engineering, ahead of his presentation at SLAS 2024.

From Society for Laboratory Automation and Screening (SLAS) 29 Jan 2024

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

The protein HOXA9 is overexpressed in most acute myeloid leukemia (AML) cases and is associated with poor patient outcomes.

12 Jan 2024

Hidden identity of blood cancer revealed

Leukemia is a common term used to refer to a form of blood cancer. However, there are different types of leukemia depending on the cell type involved.

9 Jan 2024

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

28 Dec 2023

Survival rates of black patients with leukemia soar with modern therapies

Non-Hispanic Black patients with acute myeloid leukemia (AML) are living longer, now that new therapies are available, according to a study presented by researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

11 Dec 2023

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.

11 Dec 2023

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.

8 Dec 2023

Scientists unmask molecule that fuels leukemia growth

In a study published in the journal Genes & Diseases, researchers from Beckman Research Institute of City of Hope, explored the impact of m6A modification on the maturation process of precursor microRNAs (pre-miRNAs) and its potential role in tumorigenesis.

4 Dec 2023

Myeloid Leukemia News and Research

Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer

NUS study reveals key mechanisms behind drug resistance in relapsed acute myeloid leukemia

The efficacy of the Mediterranean diet on health outcomes in adults with cancer

Innovative therapy targets and destroys leukemia stem cells

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

FDA’s plan to ban hair relaxer chemical called too little, too late

Proteogenomics provides clues about drug response in acute myeloid leukemia

Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

Hidden identity of blood cancer revealed

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

Survival rates of black patients with leukemia soar with modern therapies

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

New combinations and targeted therapies for acute myeloid leukemia on the horizon

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

Scientists unmask molecule that fuels leukemia growth

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News